U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 2531 - 2540 of 2892 results

Status:
Investigational
Source:
INN:cizolirtine [INN]
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)



Cizolirtine is a potent analgesic in mice and rats, with an efficacy superior to that of aspirin and other nonsteroid anti-inflammatory drugs. Recent studies have shown that the analgesic effect of cizolirtine could be related, at least partially, to an inhibition of spinal substance P and calcitonin gene-related peptide release. Cizolirtine has been in clinical trials for the treatment of pain and overactive bladder. Reported adverse events are: dry mouth, dizziness, nausea, vomiting, blurred vision.
Status:
Investigational
Source:
INN:icopezil [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Icopezil (previously known as CP-118,954) was developed as a selective acetylcholinesterase inhibitor for the treatment of cognitive disorders. Phase II trials of icopezil were underway in Japan and in the USA for the treatment of patients with Alzheimer's disease. However, Pfizer has discontinued these studies.
Status:
Investigational
Source:
INN:bensuldazic acid [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Bensuldazic acid was used in veterinary as an antifungal agent.
Status:
Investigational
Source:
INN:edonentan
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)


Edonentan (BMS 207940) is a highly selective biphenylsulfonamide endothelin A receptor antagonist. (11)C- and (18)F-labeled analogs of edonentan were evaluated of novel PET radioligands for imaging the endothelin-A receptor. Edonentan was in clinical trials for the treatment of heart failure however its development has been discontinued.
Status:
Investigational
Source:
INN:benzindopyrine [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Benzindopyrine belongs to anticholinergic agents. It was studied as an antipsychotic drug.
Status:
Investigational
Source:
NCT02537470: Phase 2 Interventional Completed Type 2 Diabetes Mellitus
(2015)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Remogliflozin is the active component of the pro-drug remogliflozin etabonate, which is used the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin inhibits the sodium-glucose transport proteins (SGLT), is selective for SGLT2, which is responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.
Status:
Investigational
Source:
NCT00431782: Phase 2 Interventional Completed Atrial Fibrillation
(2006)
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)


Tecarfarin (also known as ATI-5923), an anticoagulant, is a vitamin K reductase antagonist. Tecarfarin is participating in phase III clinical trials for the treatment of thromboembolism and thrombosis. On March 11, 2019, Espero BioPharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for tecarfarin for the prevention of systemic thromboembolism of cardiac origin. Tecarfarin is metabolized by esterases, escaping metabolism by the cytochrome P450 system and thereby avoiding cytochrome P450-mediated drug-drug or drug-food interactions as well as genetic variations found in the cytochrome P450 system.
Status:
Investigational
Source:
INN:iosefamic acid
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Iosefamic Acid is triiodoisophthalamic acid derivative patented by Mallinckrodt Chemical Works as x-ray contrast agent for imaging in the biliary and urinary systems and in vasography.
Status:
Investigational
Source:
INN:cetaben [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)



Cetaben has been identified as an anti-atherosclerotic hypolipidaemic substance. Cetaben is a unique, PPARα-independent peroxisome proliferator with hypolipidemic activity that inhibits cholesterol synthesis in the human hepatoma Hep-G2 cells resulting in reversible changes in Golgi morphology. Cetaben represents an exceptional type of peroxisome proliferator, specifically affecting peroxisomes, without having a negative influence on the processes of peroxisome biogenesis. Cetaben raised only the peroxisomal enzymes, acyl-CoA oxidase, glycerone-phosphate acyltransferase, D-amino-acid oxidase, catalase, and urate oxidase. Cetaben sodium has being shown to be an antiatherosclerotic agent.
Status:
Investigational
Source:
INN:sulfinalol
Source URL:

Class (Stereo):
CHEMICAL (MIXED)

Sulfinalol is a hydroxyphenylalkanolamine derivative patented by Sterling Drug Inc. as the antiarrhythmic, antihypertensive, vasodilating, and adrenergic agent. Oral administration of sulfinalol reduces the pressure of conscious spontaneously hypertensive rats. Antihypertensive action of sulfinalol was inhibited by propranolol pretreatment. Sulfinalol demonstrates effective beta-adrenergic blockade at the antihypertensive dose tested as judged by inhibition of the chronotropic responses to sympathetic stimulation and isoproterenol in pithed rats. In the renal hypertensive dog. sulfinalol lowered both systolic and diastolic blood pressure to normal values with an only slight change in heart rate.

Showing 2531 - 2540 of 2892 results